Micro-Tech (Nanjing) Co (688029) Fair Value & Analysis

Healthcare · CN · Market cap 13.8B CNY

A solid business, but screening 10% overvalued on our models.

What matters now

• Our model range runs from ¥50.08 (bear) to ¥83.46 (bull), base ¥66.77. The closer the price sits to the lower half, the larger the margin of safety.
• Quality 71/100 (solid quality) with medium evidence: read the verdict with care.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 12, 2026.

How to read this chart

60‑month range ¥56.60 – ¥225.35 · fair‑value band ¥50.08 – ¥83.46 · the ¥74.22 price screens above the ¥66.77 fair value. Dashed = 300-day average. As of Jul 12, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Micro-Tech (Nanjing) Co (688029) currently trades at ¥74.22, while our model-based Fair Value estimate is ¥66.77, implying the stock looks roughly 10.0% overvalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, Micro-Tech (Nanjing) Co generated revenue of 3.3B CNY at a net margin of 16.7%. Revenue grew 22.1% year over year. It earns a return on equity of 13.1%. The balance sheet holds a net cash position of 1.8B CNY. Fundamentals as of Jul 12, 2026

Our scenario range runs from ¥50.08 (bear case) to ¥83.46 (bull case); at ¥74.22, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 27% below its 52-week high and 18% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -10%, 688029 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings (¥99.48) versus Asset-Based (¥15.14). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Micro-Tech (Nanjing) Co.,Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of invasive medical devices in China and internationally.

Full company description

Micro-Tech (Nanjing) Co.,Ltd, together with its subsidiaries, engages in the research, development, manufacturing, and sale of invasive medical devices in China and internationally. The company offers digestive endoscopy products, including ESD, such as electric flushing device, harmony/GT gold clip, gold/titanium knife, pull clamp, three-arm clap, hemostatic titanium forceps, injection needle, vascular clamp, spray pipe, electric oil, and indigo carmine muscosal staining agent; and ERCP comprising biliary duct drainage tube, nasobiliary drainage catheter, stone removal balloon, stone retrieval basket, level 3 balloon dilation catheter, guide wire, ruyi knife, and eyemax insights. It also provides hemostasis, which includes bandage and star king clip; dilation and biopsy, such as covered biliary stent, biliary stent, intestinal stent kit with biopsy access, intestinal stent, covered intestinal stent, segmented esophageal stent system, and covered esophageal stent kit; EUS comprising ultrasonic water bag and ultrasonic needle; cell brush; and net ring toss, cleaning brush, mouth pad, and foreign body forceps. In addition, the company offers interventional radiology and surgical devices. It exports its products to approximately 90 countries and regions. The company was founded in 2000 and is headquartered in Nanjing, China.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Micro-Tech (Nanjing) Co reported revenue of ¥3.2B in FY2025 versus ¥1.9B in FY2021, a compound +13.1%/yr. Reported net income was ¥570M in FY2025, compounding +15.1%/yr from FY2021.

688029 screens 10% overvalued. Compare with Intuitive Surgical, Inc →

Peer Group

Medical Instruments & Supplies · 203 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 12, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.